Shares of Erasca Inc. (ERAS) touched a 52-week high of $24.28 during intraday trading yesterday, as the company gears up for clinical data readouts of its lead drug candidate ERAS-0015.
ERAS-0015 is a pan-RAS molecular glue designed to target RAS proteins in their active (GTP-bound) state. By doing so, it can block the signaling pathways driven by both mutant and normal RAS, potentially stopping cancer cell growth. The RAS pathway is implicated in multiple cancers.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.